Metastatic Breast Cancer Clinical Trial
— STEREO-OSOfficial title:
Extracranial Stereotactic Body Radiation Therapy (SBRT) Added to Standard Treatment Versus Standard Treatment Alone in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases
Bone metastases occur frequently during the evolution of solid tumors, either isolated or associated with visceral metastases. The incidence varies between 20 and 85% depending on the primary cancer. Breast, prostate, and lung cancers are responsible for 70% of bone metastases. Cancer with bone metastases compared to other metastatic sites is considered as associated with a better prognosis, particularly for breast and prostate cancer. Bone metastases may be present at diagnosis (synchronous metastasis) or appear at a later time (metachronous metastasis). The concept of "oligometastases" was proposed in patients with about 3 up to 5 metastases (without restriction on the primary site) and associated with an intermediate prognosis. It was hypothesized that local treatment with curative intent, aiming at the few metastatic sites, would yield long-term survival probabilities, along with systemic therapies. Long-term survivors have been reported after curative-intent treatment of metastasis in sarcoma and colorectal cancers with liver or lung metastasis. We chose to focus on bone metastasis because of their high incidence, their impact on the patient's quality of life and autonomy, and their accessibility to potentially curative radiotherapy. The systemic treatment of metastatic cancer includes hormonal therapy (breast and prostate cancer), biologically-targeted drugs and chemotherapy (all cancers). Stereotactic radiotherapy is a highly accurate technique was initially developed for performing the radiosurgery of brain tumors in patients for whom it was deemed be too difficult to proceed to classical excision surgery. In this process, a high total dose of radiation is delivered in a single fraction to a well-defined intra-cranial target. The concept of radiotherapy in stereotactic conditions was extended to one or several fractions delivered to small volumes primary tumors/ metastases in extra-cranial sites (Stereotactic Body RadioTherapy [SBRT]). At present, high control rates have been achieved for lung metastases. Similarly, very high local control rates have been reported in bone metastases after stereotactic radiotherapy. In this protocol, our purpose is to demonstrate, via a randomized phase III trial, that high doses of radiotherapy, delivered in stereotactic conditions to the bone metastases (between 1 and 5 metastases) in solid tumor patients is able to improve the survival without progression.
Status | Recruiting |
Enrollment | 196 |
Est. completion date | July 24, 2027 |
Est. primary completion date | January 24, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Patients older than 18 years and younger than 75 years 2. Good general condition: WHO performance status = 2 3. Patients with histological proof of breast, non-small cell lung, or prostate cancer Note: Histological proof can be done on the primitive tumour and/or adenopathy and/or metastatic site. 4. Absence of co-morbidity contra-indicating radio-chemotherapy or surgery 5. Primary tumor accessible to curative-intent treatment (surgery, chemoradiation…) for patients with synchronous metastases 6. Patients with between 1 and 5 synchronous or metachronous bone metastases as defined by NaF-PET or conventional SPECT-CT scan and spinal MRI (if necessary) within 6 weeks before randomization) 7. Bones metastases treatable by SBRT 8. Primary cancer considered to be controlled or accessible to curative-intent treatment (surgery, chemoradiation…) in case of locoregional recurrence for metachronous bone oligo-metastatic disease 9. Women of childbearing potential and male patients must agree to use adequate contraception for the duration of study participation and up to 3 months following completion of therapy 10. Patients who have received the information sheet, dated and signed the informed consent form 11. Affiliated to the social security system Exclusion Criteria: 1. Visceral metastases as defined by FDG-PET (F-Choline-PET or PSMA PET-CT for prostate cancer) and cerebral CT or MRI performed. 2. Previous systemic therapy for metastasis for patients with metachronous metastasis. Prostate and breast cancer patients remain eligible if hormonal treatment was initiated 6 months before enrollment 3. All bone metastasis requiring surgical treatment (spinal cord compression, fracture…) 4. More than 5 bone metastases as defined by NaF-PET or conventional SPECT-CT scan and spinal MRI (if spinal bone metastases on NaF-PET) 5. Previous cancer within the 5 years before inclusion (except basal cell carcinoma of the skin, in situ carcinoma of the uterine cervix) 6. Previous radiotherapy on bone metastasis (e.g: antalgic radiotherapy) 7. Patient enrolled in another therapeutic trial 8. Pregnant women or breast feeding mothers, 9. Hypersensitivity to the active substance (FDG and NaF or F-Choline or PSMA for prostate cancer) or to any of the excipients 10. Contraindication to MRI (in case of spinal metastases) 11. Patients deprived of liberty or placed under the authority of a tutor. Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial. Patients unable to understand the purpose of the study (language, etc.). |
Country | Name | City | State |
---|---|---|---|
France | ICO - Site Paul Papin | Angers | |
France | Centre Marie Curie | Arras | |
France | Hôpital Privé Les Bonnettes | Arras | |
France | Institut Sainte Catherine | Avignon | |
France | Centre Pierre Curie | Beuvry | |
France | Clinique Ambroise Pare | Beuvry | |
France | Clinique Tivoli Ducos | Bordeaux | |
France | Institut Bergonié | Bordeaux | |
France | Hôpital Métropole Savoie | Chambéry | |
France | Pôle Leonard de Vinci | Chambray-lès-Tours | |
France | Centre Amethyst CROM | Creil | |
France | Hôpital Henri Mondor | Créteil | |
France | Centre Léonard de Vinci | Dechy | |
France | Centre Georges Francois Leclerc | Dijon | |
France | Institut de Cancérologie de Bourgogne | Dijon | |
France | Chu Grenoble | Grenoble | |
France | Centre de Radiothérapie Hartmann | Levallois Perret | |
France | Centre Oscar Lambret | Lille | |
France | Hôpital Privé Le Bois | Lille | |
France | Centre Léon Bérard | Lyon | |
France | Institut Paoli Calmettes | Marseille | |
France | Centre de Cancérologie du Grand Montpellier | Montpellier | |
France | Institut de Cancérologie de Lorraine | Nancy | |
France | Institut de Cancérologie de l'Ouest | Nantes | |
France | Centre Catalan D'Oncologie | Perpignan | |
France | Institut Jean Godinot | Reims | |
France | Centre Eugène Marquis | Rennes | |
France | Centre Henri Becquerel | Rouen | |
France | Centre d'oncologie et radiothérapie Saint-Jean | Saint-doulchard | |
France | CHU Saint-Etienne | Saint-Étienne | |
France | GCS RISSA - Institut de cancérologie Paris Nord | Sarcelles | |
France | Centre Marie Curie | Valence | |
France | Clinique des dentellières | Valenciennes | |
France | Centre d'Oncologie Saint Yves | Vannes |
Lead Sponsor | Collaborator |
---|---|
UNICANCER | National Cancer Institute, France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression Free Survival | To evaluate the impact of SBRT on Progression-Free Survival (PFS) at 1 year according to RECIST 1.1 and PERCIST 1.0 Criteria | 1 year | |
Secondary | PFS at 2 and 3 years | Progression-Free Survival (PFS) at 2 and 3 years will be evaluated according to RECIST 1.1 and PERCIST | 2 years and 3 years after treatment | |
Secondary | Bone progression free survival at 1, 2 and 3 years | Distant bone progression at 2 and 3 years will be evaluated according to RECIST Criteria 1.1 and at 1 year according to RECIST Criteria 1.1 and PERCIST | 1, 2 and 3 years after treatment | |
Secondary | Local control at 1, 2 and 3 years | Local control will be evaluated at 1, 2 and 3 years according to RECIST Criteria 1.1 and PERCIST | 1, 2 and 3 years after treatment | |
Secondary | Cancer-specific survival | The length of time from the start of treatment for the disease until the death identified as being due to the specified cancer. | 1, 2 and 3 years after treatment | |
Secondary | Overall survival | The length of time from the start of treatment for the disease until patients are still alive. | 1, 2 and 3 years after treatment | |
Secondary | SBRT toxicities | according CTCAE 4.0 scale | 1, 2 and 3 years after treatment | |
Secondary | Patient's Quality of life | self-administered questionnaire | at baseline, 6 weeks after randomization, and 3 months, 6 months and 1, 2 and 3 years after treatment | |
Secondary | Pain score | according to Numeric Scale related to pain medication | at baseline, once a week during 2 weeks and 6 weeks after randomization, and at 3 months, 6 months and 1, 2 and 3 years after treatment | |
Secondary | Cost utility | QALYs (Quality-Adjusted Life Years) and ICERs (Incremental Cost-Effectiveness Ratios) calculation based on EQ-5D-3L questionnaire. | 6 weeks after randomization |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04872608 -
A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer
|
Phase 1 | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT02506556 -
Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05534438 -
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
|
Phase 2 | |
Recruiting |
NCT03368729 -
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT04103853 -
Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer
|
Phase 1 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Active, not recruiting |
NCT03147287 -
Palbociclib After CDK and Endocrine Therapy (PACE)
|
Phase 2 | |
Not yet recruiting |
NCT06062498 -
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05383196 -
Onvansertib + Paclitaxel In TNBC
|
Phase 1/Phase 2 | |
Recruiting |
NCT04095390 -
A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04432454 -
Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
|
Phase 2 | |
Recruiting |
NCT03323346 -
Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05744375 -
Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab
|
Phase 2 | |
Completed |
NCT02924883 -
A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy
|
Phase 2 | |
Completed |
NCT01881230 -
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
|
Phase 2/Phase 3 | |
Completed |
NCT01942135 -
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
|
Phase 3 | |
Active, not recruiting |
NCT04448886 -
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
|
Phase 2 | |
Completed |
NCT01401959 -
Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy
|
Phase 2 | |
Terminated |
NCT04720664 -
Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer
|
Phase 2 |